Samsung Bioepis Presents Five-Year Follow-Up Results of SB3 (biosimilar, trastuzumab) in P-III Study for Breast Cancer at SABCS 2021
Shots:
- The company reported the 5yr. follow up results of P-III study evaluating SB3 (trastuzumab biosimilar) vs trastuzumab in 875 patients with HER2-positive early or LA breast cancer for 4yrs. post randomization
- The results showed comparable long-term survival results b/w SB3 and trastuzumab after a median follow-up of 68mos. In 5yrs. survival analysis, EFS rate (79.8% & 75.0%), 5yrs. OS was also comparable with OS rate (92.5% & 85.4%)
- In the post-hoc analysis, SB3 was compared with non-drifted trastuzumab which showed an EFS rate (79.8% vs 82.5%), OS rate (92.5% & 91.4%). SB3 was approved in the US under the brand name Ontruzant & is marketed by Organon
Ref: Globe Newswire | Image: Samsung Bioepis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com